

# Case Study #3: InfectiClear

## WHAT THIS TECHNOLOGY DOES

InfectiClear is a diagnostic blood test which rules out infection and sepsis. The test will provide clinicians with the confidence to withhold, delay, or reduce antibiotics in the event of a low-risk score. The test, comprising a 4-gene genomic panel and interpretive software, runs on existing NHS instrumentation, requiring no upfront capital cost. It is available with a user-friendly, local or cloud-based licensed software package.

## NHS COST-SAVINGS AND PRODUCTIVITY

Adverse events associated with prescription of antibiotics for suspected respiratory infection incur [an NHS cost of £326m](#), yet up to [66% of these](#) prescriptions are inappropriate. Additionally, up to [43% of sepsis diagnoses](#) are incorrect, with potential to eliminate tens of thousands of inappropriate microbial therapy and patient monitoring courses. InfectiClear empowers clinicians to control antimicrobial use, with a [corresponding reduction](#) in associated Adverse Events.

## HOW IT SUPPORTS NHS TRANSFORMATION

### Hospital to Community

The test can identify patients at low risk of sepsis who do not require admission to a hospital and may therefore be treated within the community instead

### Treatment to Prevention

InfectiClear can prevent the unintended side effects of antimicrobial treatment, which can affect 35% of patients. Overall this avoids the 6% of patients which end up needing additional care because of these side effects.

### Analogue to Digital

These types of tests can integrate with electronic health records to improve the accessibility of patient data, and some can utilise advanced machine learning to generate their infection scores. This ability eliminates paper-based records and automates the data analysis process for healthcare professionals

## FURTHER EVIDENCE

[Diagnosing Sepsis in Primary Care: Navigating Clinical Uncertainty Across Vulnerable Patient Groups](#), Elbaroumi, O. (2026), Cureus